As of June 06. 2017, there have been 731 (728 MS, 3 CD) confirmed PML cases worldwide.
As of May 31, 2017, overall PML incidence: 4.21 per 1000 patients (95% CI 3.91 to 4.52 per 1000 patients). 24% of patients have died; 76% of patients are alive with varying levels of disability.
As of May 31, 2017, approximately 170,900 patients received natalizumab in post-marketing setting worldwide.
After the re-approval of Tysabri® (Natalizumab), there were the expected/feared PML disorders. I have generated a table with the main available data from June 2008 to june 2016.
I would be grateful for additional information via comment or e-mail. Tysabri®, Avonex®, Rebif® & Copaxone® are trademarks.